[99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.

@article{Gabriel201199mTcdemotensinVB,
  title={[99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.},
  author={Michael Gabriel and Clemens Decristoforo and Ewald Woell and Wolfgang Eisterer and Berthold A Nock and Theodosia Maina and Roy Moncayo and Irene Johanna Virgolini},
  journal={Cancer biotherapy & radiopharmaceuticals},
  year={2011},
  volume={26 5},
  pages={
          557-63
        }
}
  • Michael Gabriel, Clemens Decristoforo, +5 authors Irene Johanna Virgolini
  • Published in
    Cancer biotherapy…
    2011
  • Medicine
  • PURPOSE Neurotensin subtype 1 receptor overexpression is found in a variety of human tumors. The aim of this pilot/phase I study was to assess the safety profile, pharmacokinetics, and imaging characteristics of (99m)Tc-Demotensin VI in tumor patients. METHODS Scintigraphy with (99m)Tc-Demotensin VI was performed in 14 patients (2 female and 12 male) with advanced tumor stages. The diagnoses were pancreatic adenocarcinoma (n=4), small cell lung cancer (SCLC) (n=4), non-small cell lung cancer… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-4 OF 4 CITATIONS

    Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Somatostatin receptor SPECT

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 24 REFERENCES

    Use of neurotensin analogue In-111-DTPA-neurotensin (IN-111MP2530) in diagnosis of pancreatic adenocarcinoma

    • AC Froeberg, CH van Eijck, MC Verdijsseldonck
    • Eur J Nucl Med Mol Imaging 2004;31(Suppl. 2):S392
    • 2004
    VIEW 3 EXCERPTS
    HIGHLY INFLUENTIAL

    Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

    68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

    VIEW 1 EXCERPT

    Candidates for peptide receptor radiotherapy today and in the future.

    VIEW 1 EXCERPT